Study guide
Immunisation and cancer screening entry points
AMC CAT MCQ Examination AMC Part 1
Track your progress as you read
Finished sections get a check mark.
1 Acute Coronary Syndromes & ECG Localization
ACS recognition and ECG localisation Reperfusion and infarction complications
2 Heart Failure, Cardiogenic Shock & Cardiac Arrhythmias
Heart failure assessment and treatment Arrhythmias and conduction emergencies
3 Systemic Hypertension & Peripheral Vascular Disease
Blood pressure and cardiovascular risk Secondary hypertension and arterial disease
4 Valvular Heart Disease, Infective Endocarditis & Pericarditis
Aortic and mitral valve disease Endocarditis and pericardial emergencies
5 Asthma & COPD Acute Flares and Maintenance
Asthma and COPD diagnosis and maintenance Acute asthma and COPD exacerbations
6 Pneumonia, pleural disease and respiratory failure
Pneumonia and infected pleural collections Pulmonary embolism, effusions and pneumothorax Respiratory failure, ARDS and sepsis
7 GI bleeding, bowel inflammation and malabsorption
GI bleeding assessment and resuscitation Varices, ulcers, reflux and lower GI bleeding IBD patterns and severe colitis assessment IBD treatment, coeliac disease and IBS
8 Chronic Liver Disease, Cirrhosis Complications & Acute Hepatitis
Cirrhosis diagnosis and prognosis Decompensation, viral hepatitis and surveillance
9 Diabetes, thyroid and adrenal disease
Diabetes diagnosis and ongoing care DKA, HHS and complication monitoring Thyroid disease assessment Thyroid emergencies and adrenal disease
10 Acute Kidney Injury, Chronic Kidney Disease & Fluid/Electrolyte Emergencies
AKI and chronic kidney disease Potassium and sodium emergencies
11 Anaemias, Inflammatory Arthropathies & Geriatric Comprehensive Assessment
Anaemia, bruising and blood disorders Arthritis, autoimmune disease and geriatric care
12 Evaluation of the Acute Abdomen, Peritonitis & Appendicitis
Abdominal pain, peritonitis and resuscitation Appendicitis diagnosis and treatment Perforation and mesenteric ischaemia
13 Small and Large Bowel Obstruction & Colorectal Surgical Pathology
Small bowel obstruction Colonic obstruction, volvulus and cancer recognition Colorectal care, diverticulitis and anorectal symptoms
14 Gallbladder Disease, Biliary Tract Infections & Acute Pancreatitis
Gallstones and biliary obstruction Cholangitis and pancreatitis diagnosis Pancreatitis severity and treatment
15 Advanced Trauma Life Support, Primary Survey & Life-Threatening Thoracic Injuries
Trauma primary survey and adjuncts Chest trauma and immediate threats
16 Traumatic Brain Injury, Intracranial Haemorrhage & Spinal Cord Clearance
Head injury, imaging and haemorrhage Herniation and spinal cord injury
17 Major Fractures, Joint Dislocations & Acute Compartment Syndrome
Fracture assessment and open injuries Compartment syndrome, dislocations and pelvic injury
18 Thermal Burns, Haemorrhagic Shock Resuscitation & Surgical Wound Care
Burn assessment and fluid resuscitation Bleeding shock, wound care and tetanus
19 Aortic Aneurysms & Acute Arterial Limb Ischaemia
Aneurysm recognition and planned care Ruptured aneurysm and acute limb ischaemia
20 Urological Emergencies, Testicular Torsion & Haematuria Investigation
Retention, stones and obstructed infection Scrotal pain and haematuria
21 Preoperative Risk Stratification & Postoperative Surgical Complications
Preoperative assessment and medicines Postoperative complications and prevention
22 Early Pregnancy Bleeding, Ectopic Pregnancy & Antenatal Screening
Miscarriage and ectopic pregnancy Antenatal screening and early-pregnancy comparisons
23 Hypertensive Disorders of Pregnancy & Medical Complications in Pregnancy
Pregnancy hypertension and preeclampsia Eclampsia, HELLP and antepartum bleeding
24 Intrapartum Monitoring, Postpartum Haemorrhage & Obstetric Emergencies
Labour physiology and CTG assessment CTG response and postpartum haemorrhage Obstetric emergencies and preterm birth
25 Abnormal Uterine Bleeding, Pelvic Pain & Endometriosis
Abnormal bleeding and structural causes Endometrial sampling and endometriosis PCOS diagnosis and long-term care
26 Contraception, Emergency Contraception & Pregnancy Termination
Contraceptive choice and missed pills Emergency contraception and abortion
27 Australian Cervical Screening Program & Gynaecological Malignancies
Cervical screening and cervical cancer Endometrial and ovarian cancer
28 Neonatal Resuscitation, Congenital Conditions & Neonatal Jaundice
Newborn resuscitation, Apgar and cyanosis Neonatal jaundice assessment Jaundice treatment and congenital screening
29 Developmental Milestones, Growth Charts & Failure to Thrive
Developmental milestones Regression, autism and support Faltering growth and developmental comparisons
30 The Limping Child, Septic Arthritis vs Transient Synovitis & Paediatric Hip Conditions
Limp assessment and septic-joint risk Joint-infection management and Perthes disease SUFE and paediatric hip comparisons
31 Croup, Bronchiolitis, Paediatric Asthma & Anaphylaxis
Croup Bronchiolitis Paediatric asthma Paediatric anaphylaxis
32 Evaluation of the Febrile Child, Sepsis & Meningococcal Disease
Febrile neonates and young infants Meningococcal disease and paediatric sepsis Bacterial meningitis and CSF interpretation Kawasaki disease and follow-up
33 Paediatric Surgical Abdomen, Dehydration & Child Protection / Non-Accidental Injury
Pyloric stenosis Intussusception and dehydration Child protection and injury assessment
34 The Mental State Examination & Suicide Risk Stratification
Mental state examination and psychotic symptoms Suicide formulation and mental health law
35 Major Depressive Disorder, Bipolar Affective Disorder & Mood Stabilisers
Depression assessment and treatment Serotonin toxicity and bipolar presentations Mood stabilisers and ECT
36 Generalised Anxiety, Panic Disorder, PTSD & Obsessive-Compulsive Disorder
Anxiety, panic and agoraphobia OCD and trauma-related disorders
37 Schizophrenia, Acute Psychosis & Antipsychotic Management
Psychosis assessment and antipsychotics Clozapine and severe adverse effects
38 Substance Use Disorders & Acute Withdrawal Syndromes
Substance disorders and alcohol withdrawal Wernicke disease, opioids and stimulants
39 Delirium vs Dementia, Perinatal Mood Disorders & Paediatric Psychiatry
Delirium and dementia assessment Cognitive behaviour, perinatal and childhood psychiatry
40 Medicare, PBS, AHPRA & Good Medical Practice Framework
Australian health services and Medicare PBS access and professional registration Professional boundaries and notifications
41 Informed Consent (Rogers v Whitaker), Mental Capacity & Involuntary Treatment
Consent, material risks and young people Capacity, refusal and substitute decisions
42 Patient Privacy, Confidentiality Exceptions & Mandatory Notifications
Privacy, disclosure and child reporting Driving fitness and threat disclosure
43 First Nations health and preventive care
First Nations health, determinants and cultural safety Community care, Item 715 and CTG medicines Immunisation and cancer screening entry points Screening pathways and primary CVD prevention
44 Epidemiological Metrics, Clinical Study Designs & Notifiable Communicable Diseases
Epidemiology, calculations, bias and surveillance
45 Neurological presentations
Stroke, TIA and focal weakness Headache, facial pain and vertigo Seizures, collapse and altered consciousness Numbness, movement disorders and generalised weakness
46 Musculoskeletal pain
Back, neck, bone and soft tissue pain
47 Eye presentations
Altered vision and retinal disease Red eye, ocular injury and discharge
48 Ear, nose, throat and oral health
Ear pain, hearing loss and tinnitus Nasal problems, neck lumps, hoarseness and dysphagia Toothache, mouth symptoms, dry mouth and halitosis
49 Skin, hair and nails
Rash, itch, infection and skin ulcers Skin lesions, hair loss and nail abnormalities
50 Breast health and feeding
Breast lumps, discharge and breastfeeding problems
51 Sexual and reproductive presentations
Genital symptoms, discharge and pelvic infection Menopause, prolapse and urinary symptoms Infertility and sexual dysfunction
52 Palliative care and carers
The dying patient, symptoms and carers
53 Eating disorders and personality care
Eating disorders, obesity and weight change Personality difficulties, self-harm and complex care
54 Sleep presentations
Insomnia, snoring and daytime sleepiness
55 Poisoning, resuscitation and environmental emergencies
Poisoning, toxidromes and antidote decisions Cardiopulmonary arrest, choking and emergency help Bites, stings, heat, cold and drowning
56 Communication, rights and professional practice
Communication, handover, errors and complaints Healthcare rights, inclusive care and equitable access Certificates, deaths, CPD and supervision Telehealth, images, prescribing and doctors' health
57 Genetics, research and donation
Genetic testing, research and organ donation
58 Travel, fever and outbreaks
Fever, travellers and outbreak response
Immunisation and cancer screening entry points
Key Takeaways Explain This Topic AI
The adult NIP pneumococcal programme changed to 21-valent vaccine from July 2026.
National lung screening targets eligible high-risk adults aged 50–70.
Bowel-screening participants aged 45–49 can request their first kit.
Last updated: October 2026
Australian National Immunisation Program & Cancer Screening Programs
Preventive medicine and population screening form the backbone of primary healthcare in Australia. Medical practitioners must demonstrate mastery of the Australian National Immunisation Program (NIP) schedule, organized population cancer screening algorithms, and absolute cardiovascular disease risk assessment to optimize health outcomes and prevent premature morbidity and mortality.
The Australian National Immunisation Program (NIP) Schedule
The National Immunisation Program (NIP), funded by the Commonwealth and State/Territory governments, provides free vaccines to eligible Australians across defined life stages. Vaccinations must be registered promptly on the Australian Immunisation Register (AIR).
Clinical Nuances of Childhood Immunisation
Hepatitis B at Birth : Administered within 24 hours of birth to prevent perinatal mother-to-child transmission. If the mother is hepatitis B surface antigen (HBsAg) positive, the neonate must receive both the hepatitis B vaccine and Hepatitis B Immunoglobulin (HBIG) within 12 hours of birth in separate anatomical limbs.
Rotavirus Vaccine Safety : Live-attenuated oral vaccine with strict age boundaries to minimize the rare risk of intussusception. The first dose must be given between 6 weeks and 14 weeks and 6 days of age; the final dose must be completed by 24 weeks and 6 days of age. Never initiate rotavirus vaccination in infants aged 15 weeks or older.
MMR vs MMRV : The combination MMRV (measles-mumps-rubella-varicella) vaccine carries a higher rate of post-vaccination febrile convulsions if given as the first measles-containing dose. Therefore, MMR is given at 12 months, and MMRV is reserved for 18 months.
Adolescent School-Based Immunisation Programs
Year 7 (Aged 12 to 13 years) :
Human Papillomavirus (9vHPV - Gardasil 9) : Administered as a single dose in the national school program for immunocompetent adolescents. Australia transitioned from a two-dose to a single-dose schedule based on robust global evidence demonstrating equivalent long-term protection against high-risk oncogenic HPV types (16, 18, 31, 33, 45, 52, 58) and anogenital wart types (6, 11). Immunocompromised individuals still require a 3-dose schedule.
dTpa Booster : Reduced-antigen diphtheria-tetanus-acellular pertussis booster.
Year 10 (Aged 15 to 16 years) :
Meningococcal ACWY (MenACWY) : Quadrivalent conjugate booster targeting high-carriage adolescent cohorts to induce herd immunity.
Maternal Immunisation in Pregnancy
Maternal vaccination provides dual protection by preventing severe maternal morbidity and conferring passive protection to the neonate via transplacental IgG antibodies before the infant can be immunized:
dTpa (Pertussis-containing vaccine) : Recommended and funded for administration between 20 and 32 weeks of gestation during EVERY pregnancy , regardless of the interval since a previous dose. Receiving the vaccine during this window maximizes maternal antibody production and transplacental transfer.
Influenza Vaccine : Inactivated influenza vaccine is recommended and funded at any stage (trimester) of pregnancy , providing protection during maternal gestation and reducing infant influenza hospitalisation during the first 6 months of life.
Respiratory Syncytial Virus (RSV) Vaccine : Recombinant RSV prefusion F protein vaccine (Abrysvo) administered between 28 and 36 weeks of pregnancy to protect infants from severe lower respiratory tract illness (bronchiolitis and pneumonia).
Adult and risk-based immunisation
From July 2026, adult NIP pneumococcal vaccination uses 21vPCV (Capvaxive), replacing Prevenar 13 and Pneumovax 23 on the adult NIP. It is funded from 65 for non-Indigenous adults, 25 for First Nations adults and 18 for specified risk conditions. After previous pneumococcal vaccination, generally wait at least twelve months. The childhood vaccine and schedule differ.
Shingrix is a two-dose recombinant zoster vaccine, funded from 65 years, from 50 for First Nations adults, and for specified high-risk immunocompromised adults from 18. Influenza is annual for funded groups; use the age-appropriate current-season formulation rather than an obsolete fixed valency. RSV vaccination and infant monoclonal-antibody protection have separate age/risk/funding pathways. Check the current Handbook and state program rather than treating TGA approval as automatic NIP funding.
Review catch-up, occupational exposure, pregnancy and immunocompromise. A severe allergic reaction to a previous dose/component is different from a mild cold or local soreness. Live vaccines have pregnancy/immunocompromise restrictions; inactivated products have different considerations. Document informed consent, batch/site, adverse events and AIR reporting under current requirements.
Check history before a vaccine decision
For an older adult, confirm previous doses, age, risk conditions and the current vaccine product rather than repeating an old schedule automatically. A TGA-approved product is not necessarily funded for every age group. Explain expected reactions and serious warning signs, document consent, product, batch and administration, and use the adverse-event reporting pathway when indicated. A missed childhood dose usually leads to catch-up planning rather than restarting every series.
Australia's Four Organised Population Cancer Screening Programs
Australia maintains four nationwide, evidence-based, government-funded population cancer screening programs designed to detect malignancies at early, curable stages.
Primary references (checked 7 October 2026): Current Immunisation Handbook ; 2026 adult pneumococcal update ; National lung screening .